Trials / Completed
CompletedNCT02691793
Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single arm, pilot study of Sunitinib in patient with RET fusion positive, FGFR2 fusion/FGFR mutation Refractory solid tumor and/or specific sensitivity to Sunitinib by Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy. To investigate the efficacy and safety of Sunitinib in patient with Refractory solid tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sunitinib | sunitinib 37.5mg QD |
Timeline
- Start date
- 2017-11-20
- Primary completion
- 2019-08-30
- Completion
- 2019-11-19
- First posted
- 2016-02-25
- Last updated
- 2022-06-15
Locations
1 site across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02691793. Inclusion in this directory is not an endorsement.